Molecular Diagnosis & Therapy

, Volume 16, Issue 1, pp 1–6

Molecular Signatures of Lung Cancer

Defining New Diagnostic and Therapeutic Paradigms

Authors

    • Department of Medicine, Vanderbilt-Ingram Comprehensive Cancer CenterVanderbilt University
  • Carlos L. Arteaga
    • Department of Medicine, Vanderbilt-Ingram Comprehensive Cancer CenterVanderbilt University
    • Department of Cancer Biology, Vanderbilt-Ingram Comprehensive Cancer CenterVanderbilt University
    • Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer CenterVanderbilt University
Current Opinion

DOI: 10.1007/BF03256423

Cite this article as:
Balko, J.M. & Arteaga, C.L. Mol Diagn Ther (2012) 16: 1. doi:10.1007/BF03256423
  • 30 Views

Abstract

Molecular profiling holds great promise for improving our ability to diagnose, prognosticate, and select individualized treatments for lung cancer patients. However, using multidimensional data and novel technologies to derive these profiles is limited by our ability to employ the assay in a clinical scenario where it can impact the course of disease. Although many molecular signatures have been reported in lung cancer, as of yet, few have been sufficiently validated for widespread clinical use. Recently, several novel signatures have been reported, which address critical aspects of patient care and/or demonstrate improved efforts for appropriate clinical validation. Here, we present our opinion on the current state of the field of molecular signatures in lung cancer.

Copyright information

© Adis Data Information BV 2012